Ocular Therapeutix reported a net loss of $15.6 million, or $0.54 per share, in the third quarter of 2017 compared with a net loss of $9.6 million, or $0.39 per share, in 2016’s third quarter.
Revenue for the quarter was $0.5 million, attributed to sales of ReSure sealant, according to a company press release.
Total costs and operating expenses for the quarter were $15.7 million compared with $9.7 million a year ago. The increase was attributed to an initiative to enhance operations and reduce expenses surrounding the delayed launch of (Read more...)
Uncategorized